Trial
NCT00799448
Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novo Nordisk A/S
Collaborators
—
Condition
Diabetes
Intervention
repaglinide
Why stopped
Low recruitment status
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-20